Immunoglobulin May Prevent Infections in Patients With Multiple Myeloma
Bibliographic record
Abstract
Multiple Myeloma: Multiple MyelomaBispecific antibodies targeting the BCMA protein are increasingly employed in the treatment of multiple myeloma, with two agents recently approved by the FDA to treat this blood cancer. While anti-BCMA bispecific antibodies have exhibited impressive efficacy against heavily pretreated multiple myeloma, there has been a high rate of serious, sometimes lethal, infections in patients receiving these therapies, explained Guido Lancman, MD, Clinical Associate at the Princess Margaret Cancer Centre of the University Health Network and Adjunct Assistant Professor at the University of Toronto. Prior research from Lancman and colleagues suggested that the increased risk of infection during anti-BCMA therapy may be caused by treatment-induced depletion of the patient's own antibodies, a condition known as hypogammaglobulinemia. “Since antibodies are key components of the immune response, the inability to make antibodies leaves patients vulnerable to all sorts of viral and bacterial infections,” Lancman noted. “As more and more patients start receiving BCMA-targeted bispecific antibodies, it is critical that physicians become aware of this toxicity and learn how to manage it.” Study Details Lancman and colleagues hypothesized that supplementing patient antibody levels through intravenous (IV) delivery of donor antibodies—also known as immunoglobulins (Ig)—might mitigate their risk of infection. To test this hypothesis, they conducted a retrospective analysis of 37 patients with heavily pretreated multiple myeloma who had received treatment with an anti-BCMA bispecific antibody. All patients were enrolled in one of four clinical trials at Mount Sinai Hospital between 2019 and 2022. Among the 26 patients who experienced clinical responses to an anti-BCMA bispecific antibody, 100 percent had severe hypogammaglobulinemia (defined as IgG levels below 200 mg/dL), and approximately 92 percent received IVIg at some point during treatment. During a combined 424 months of follow-up, patients experienced a total of 118 infections, including 26 severe infections (grades 3-5) among 15 patients. The authors found that the rate of severe infection was 90 percent lower during times when patients were receiving IVIg compared to when they were not receiving IVIg. No other significant risk factors for infection were found in this study. “This study demonstrates that IVIg is associated with a substantially reduced risk of serious infections in patients receiving anti-BCMA bispecific antibodies,” Lancman said. “Given the very high rates of serious infections and deaths in patients receiving these treatments, this study supports a proactive rather than a reactive approach, meaning initiation of IVIg prophylaxis from the beginning rather than waiting for patients to experience complications.” Since the patients' own antibodies did not recover while on treatment or during periods off treatment lasting up to 13 months, Lancman suggested that IVIg may need to be given throughout the duration of anti-BCMA bispecific antibody therapy and possibly for some time afterward. However, he noted that alternative strategies will need to be considered if anti-BCMA therapies are used for earlier lines of treatment. “It would not be feasible to maintain every multiple myeloma patient on IVIg indefinitely, so hopefully we will start to see more fixed-duration studies of these bispecific antibodies in order to allow the immune system the opportunity to recover,” he noted. Limitations of the study include the small sample size and the non-random use of IVIg. In addition, since the analysis was conducted on patients enrolled in clinical trials at a single institution, the results may not be representative of the general patient population.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".